Research programme: extracorporeal antibody therapies - Premier Biomedical

Drug Profile

Research programme: extracorporeal antibody therapies - Premier Biomedical

Alternative Names: Sequential dialysis therapy - Premier Biomedical

Latest Information Update: 31 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Premier Biomedical
  • Developer Premier Biomedical; University of Texas at El Paso; William Beaumont Army Medical Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Cytokine inhibitors; Glutamate modulators; Immunomodulators; Neurotransmitter inhibitors; Neurotransmitter modulators; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Breast cancer; Cancer metastases
  • Research Alzheimer's disease; Amyotrophic lateral sclerosis; Brain injuries; Cockayne syndrome; Neurofibromatoses
  • No development reported Major depressive disorder; Retinitis pigmentosa

Most Recent Events

  • 26 Jan 2018 Premier Biomedical is seeking partners for its cancer research technology development as of 26 Jan 2018. http://www.premierbiomedical.com/
  • 09 May 2017 Early research development is ongoing for Alzheimer's disease and Brain injuries in USA
  • 09 May 2017 Premier Biomedical is seeking partners to develop sequential dialysis technique for development of extracorporeal antibody therapies as of 18 May 2017. http://www.premierbiomedical.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top